Page 38 - 72_04

BEATRIZ MARTÍNEZ POVEDA Y COLS. AN. R. ACAD. NAC. FARM.

(34) CÁRDENAS, C.; QUESADA, A. R. and MEDINA, M. A. (2004): Efects of ursolic acid
(35) on diferent steps of the angiogenic process. Biochem. Biophys. Res. Commun.
(36) 320: 402-408.
(37) MARTÍNEZ-POVEDA, B.; QUESADA, A. R. and MEDINA, M. A. (2005): Hyperforin,
(38) a bio-active compound of St. John’s wort, is a new inhibitor of angiogenesis
(39) targeting several key steps of the process. Int. J. Cancer 117: 775-780.
MARTÍNEZ-POVEDA, B.; QUESADA, A. R. and MEDINA, M. A. (2005): Hypericin in
the dark inhibits key steps of angiogenesis in vitro. Eur. J. Pharmacol. 516:
97-103.
LAVIE, G.; MANDEL, M.; HAZAN, S.; BARLIYA, T.; BLANK, M.; GRUNBAUM, A.; MERUE-
LO, D. and SOLOMON, A. (2005): Anti-angiogenic activities of hypericin in vivo:
Potential for ophthalmologic applications. Angiogenesis 8: 35-42.
QUINEY, C.; BILLARD, C.; MIRSHANI, P.; FOURNERON, J. D. and KOLB, J. P. (2006):
Hyperforin inhibits MMP-9 secretion by B-CLL cells and microtubule forma-
tion by endothelial cells. Leukemia 20: 583-589.
SCHEMPP, C. M.; KISS, J.; KIRKIN, V.; AVERBECK, M.; SIMON-HAARHAUS, B.; KRE-
MER, B.; TERMEER, C. C.; SLEEMAN, J. and SIMON, J. C. (2005): Hyperforin acts
as an angiogenesis inhibitor. Planta Med. 71: 999-1004.

598